Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo

Diabetes Care

Volumn 23, Issue 5, 2000, Pages 644-649

  Heinemann, Lutz ^a,b   Linkeschova, Renata ^a   Rave, Klaus ^a   Hompesch, Beate ^a   Sedlak, Martin ^a   Heise, Tim ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Profil Institute for Metabolic Research   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN GLARGINE; ISOPHANE INSULIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN TREATMENT; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL;

EID: 0034117810     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.23.5.644     Document Type: Article

References (17)

1. Hilgenfeld R, Dörschug M, Geisen K: Controlling insulin bioavailability by crystal contact engineering. Diabetologia 35 (Suppl. 1):A193, 1985
2. Dreyer M, Pein M, Schmidt C, Heidtmann B, Schlünzen M, Rosskamp R: Comparison of the pharmacokinetics/dynamics of Gly(A21)-Arg(B31, B32)-human-insulin (HOE71GT) with NPH-insulin following subcutaneous injection by using euglycaemic clamp technique. Diabetologia 37 (Suppl. 1):A78, 1994
3. Soon PC, Matthews DR, Rosskamp R, Herz M, Kurzhals R: 24h profile of action of biosynthetic long-acting insulin (HOE901) tested in normal volunteers by glucose clamp methodology. Diabetes 46 (Suppl. 1): 161A, 1997
4. Rosskamp R, Park G: Long-acting insulin analogs. Diabetes Care 22 (Suppl. 2): B109-B113, 1999
5. Ipp E, Sinai Y, Bar-Oz B, Nesher R, Cerasi E: Somatostatin impairs clearance of exogenous insulin in humans. Diabetes 36: 673-677, 1987
6. Allison DB, Paultre F, Maggio C, Mezzitis N, Pi-Sunyer FX: The use of areas under curves in diabetes research. Diabetes Care 18:245-250, 1995
7. Starke AAR, Heinemann L, Hohmann A, Berger M: The action profiles of human NPH insulin preparations. Diabet Med 6: 239-244, 1989
8. Heinemann L, Breuer J, Cebulla D, Wüssel B, Bender R, Heise T: Wirkungsprofile von Normalinsulin, NPH-Insulin sowie einer 25/75-Mischung hergestellt aus gentechnologischem bzw: semisynthetischem Humaninsulin. Diabetes und Stoffw 5:157-163, 1996
9. Lepore M, Kurzhals R, Pampanelli S, Giuseppe C, Fanelli C, Bolli GB: Pharmacokinetics and dynamics of s.c. injection of the long-acting insulin glargine (HOE901) in TIDM. Diabetes 48 (Suppl. 1):A97, 1999
10. Owens D, Luzio S, Beck P, Coates P, Tinbergen J, Kurzhals R: The absorption of the insulin analogue HOE901 from different sues in healthy subjects. Diabetes 46 (Suppl. 1):329A, 1997
11. Drejer K, Kruse V, Larsen DU, Hougaard P. Bjorn S, Gammeltoft S: Receptor binding and tyrosine kinase activation by insulin analogues with extreme affinities studied in human hepatoma HepG2 cells. Diabetes 40:1488-1495, 1991
12. Jehle PM, Micheler C, Jehle DR, Breitig D, Boehm BO: Inadequate suspension of neutral protamine Hagedorn (NPH) insulin in pens. Lancet 354:1604-1607, 1999
13. Scholtz HE, van Niekerk N, Meyer BH, Rosenkranz B: An assessment of the variability in the pharmacodynamics (glucose lowering effect) of HOE901 compared to NPH and ultralente human insulins using the euglycaemic clamp technique. Diabetologia 42 (Suppl. 1): A235, 1999
14. Ratner RE, Hirsch IB, Mecca TE, Wilson CA: Efficacy and safety of insulin glargine in subjects with type 1 diabetes: a 28 week randomized, NPH insulin-controlled trial. Diabetes 48 (Suppl. 1):A120, 1999
15. Rosenstock J, Schwartz S, Clark C, Edwards M, Donley D: Efficacy and safety of HOE901 (insulin glargine) in subjects with type 2 diabetes: a 28 week randomized, NPH insulin-controlled trial. Diabetes 48 (Suppl. 1):A100, 1999
16. Heise T, Weyer C, Serwas A, Heinrichs S, Osinga J, Roach P, Woodworth JR, Gudat U, Heinemann L: Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin. Diabetes Care 21: 800-803, 1998
17. Rave K, Heinemann L, Puhl L, Gudat U, Woodworth JR, Weyer C, Heise T: Premixed formulations of insulin lispro: activity profiles in type 1 diabetic patients (Letter). Diabetes Care 22:865-866, 1999